Cabazitaxel

Cabazitaxel
Clinical data
Trade names	Jevtana
Other names	XRP-6258
AHFS/Drugs.com	Monograph
MedlinePlus	a611009
License data	US DailyMed: Cabazitaxel;
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	L01CD04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl benzoate;
CAS Number	183133-96-2 ;
PubChem CID	9854073;
IUPHAR/BPS	6798;
DrugBank	DB06772 ;
ChemSpider	8029779 ;
UNII	51F690397J;
KEGG	D09755 ; D10452;
ChEBI	CHEBI:63584 ;
ChEMBL	ChEMBL1201748 ;
CompTox Dashboard (EPA)	DTXSID40171389 ;
ECHA InfoCard	100.205.741
Chemical and physical data
Formula	C45H57NO14
Molar mass	835.944 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C;
	InChI InChI=1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,23-56-30)59-25(2)47/h11-20,28-30,32-35,37,48,53H,21-23H2,1-10H3,(H,46,52)/t28-,29-,30+,32-,33+,34+,35-,37-,43+,44-,45+/m0/s1 ; Key:BMQGVNUXMIRLCK-OAGWZNDDSA-N ;
	(what is this?) (verify)

Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. It is available as a generic medication.